Virios Therapeutics IncChange company Symbol lookupSelect an option...VIRI Virios Therapeutics IncTCBS Texas Community Bancshares IncUPC Universe Pharmaceuticals IncMHH Mastech Digital IncGCTK GlucoTrack IncKODK Eastman Kodak CoFYBR Frontier Communications Parent IncTPNEF Cub Energy IncECC Eagle Point Credit Co LLCCPHI China Pharma Holdings IncGo
Virios Therapeutics, Inc., formerly Virios Therapeutics, LLC., is a development-stage biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Its lead development candidate is IMC-1, which is a fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication. Its HSV-1 root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatigue syndrome and functional somatic syndrome. The Company is developing its initial candidate, IMC-1, for people who are suffering from fibromyalgia.
|
|
|
|
| |
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2022. All rights reserved.